<VariationArchive VariationID="1457825" VariationName="NM_024529.5(CDC73):c.626_629del (p.Lys209fs)" VariationType="Deletion" Accession="VCV001457825" Version="5" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-14" DateCreated="2022-03-28" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1471392" VariationID="1457825">
      <GeneList>
        <Gene Symbol="CDC73" FullName="cell division cycle 73" GeneID="79577" HGNC_ID="HGNC:16783" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q31.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="193122031" stop="193254815" display_start="193122031" display_stop="193254815" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="193091087" stop="193223944" display_start="193091087" display_stop="193223944" Strand="+" />
          </Location>
          <OMIM>607393</OMIM>
          <Haploinsufficiency last_evaluated="2022-04-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDC73">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-04-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CDC73">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_024529.5(CDC73):c.626_629del (p.Lys209fs)</Name>
      <CanonicalSPDI>NC_000001.11:193141961:AAACA:A</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1q31.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="193141962" stop="193141965" display_start="193141962" display_stop="193141965" variantLength="4" positionVCF="193141961" referenceAlleleVCF="TAAAC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="193111092" stop="193111095" display_start="193111092" display_stop="193111095" variantLength="4" positionVCF="193111091" referenceAlleleVCF="TAAAC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>K209fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_507" sequenceAccession="LRG_507">
            <Expression>LRG_507:g.25006_25009del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.193111093_193111096del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.193111093_193111096del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.193141963_193141966del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.193141963_193141966del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012691.1" sequenceAccession="NG_012691" sequenceVersion="1" change="g.25006_25009del">
            <Expression>NG_012691.1:g.25006_25009del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024529.5" sequenceAccession="NM_024529" sequenceVersion="5" change="c.626_629del" MANESelect="true">
            <Expression>NM_024529.5:c.626_629del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_078805.3" sequenceAccession="NP_078805" sequenceVersion="3" change="p.Lys209fs">
            <Expression>NP_078805.3:p.Lys209fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2103126261" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_024529.5(CDC73):c.626_629del (p.Lys209fs) AND Parathyroid carcinoma" Accession="RCV001949345" Version="3">
        <ClassifiedConditionList TraitSetID="834">
          <ClassifiedCondition DB="MedGen" ID="C0687150">Parathyroid carcinoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_024529.5(CDC73):c.626_629del (p.Lys209fs) AND Hyperparathyroidism 1" Accession="RCV003464317" Version="1">
        <ClassifiedConditionList TraitSetID="835">
          <ClassifiedCondition DB="MedGen" ID="C1840402">Hyperparathyroidism 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-06-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-06-16" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2022-03-28" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12434154</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23029104</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32590342</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="835" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1734" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HYPERPARATHYROIDISM, FAMILIAL ISOLATED PRIMARY</ElementValue>
                <XRef Type="MIM" ID="145000" DB="OMIM" />
                <XRef Type="Allelic variant" ID="613733.0031" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hyperparathyroidism 1</ElementValue>
                <XRef ID="319534" DB="GeneTests" />
                <XRef ID="Hyperparathyroidism+1/8597" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007767" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HRPT1</ElementValue>
                <XRef Type="MIM" ID="145000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FIHP</ElementValue>
                <XRef Type="MIM" ID="145000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">CDC73-Related Disorders</Attribute>
                <XRef ID="226120" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18253" />
                <XRef ID="18253" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of CDC73-related disorders includes the following phenotypes: Hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Primary hyperparathyroidism, the main finding of HPT-JT syndrome, occurs in up to 95% of affected individuals; onset is typically in late adolescence or early adulthood. HPT-JT-associated primary hyperparathyroidism is usually caused by a single parathyroid adenoma. In approximately 10%-15% of individuals, primary hyperparathyroidism is caused by parathyroid carcinoma. Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome. Although benign, these tumors can be locally aggressive and may continue to enlarge if not treated. Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) Wilms tumor have also been reported. Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome. Parathyroid carcinoma. Most parathyroid carcinomas are functional, resulting in hyperparathyroidism and a high serum calcium level; however, nonfunctioning parathyroid carcinomas are also rarely described in individuals with a CDC73-related disorder. A germline CDC73 pathogenic variant has been identified in 20%-29% of individuals with apparently sporadic parathyroid carcinoma. Familial isolated hyperparathyroidism (FIHP). FIHP is characterized by primary hyperparathyroidism without other associated syndromic features. Individuals with CDC73-related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a CDC73 pathogenic variant has not been identified.</Attribute>
                <XRef ID="NBK3789" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301744</ID>
                <ID Source="BookShelf">NBK3789</ID>
              </Citation>
              <XRef ID="99879" DB="Orphanet" />
              <XRef ID="C1840402" DB="MedGen" />
              <XRef ID="MONDO:0007767" DB="MONDO" />
              <XRef Type="MIM" ID="145000" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="834" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3270" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Parathyroid gland carcinoma</ElementValue>
                <XRef ID="MONDO:0012004" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Parathyroid cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CDC73-Related Parathyroid Carcinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Parathyroid carcinoma</ElementValue>
                <XRef ID="Parathyroid+carcinoma/5598" DB="Genetic Alliance" />
                <XRef ID="HP:0006780" DB="Human Phenotype Ontology" />
                <XRef ID="255037004" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PRTC</ElementValue>
                <XRef Type="MIM" ID="608266" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of CDC73-related disorders includes the following phenotypes: Hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Primary hyperparathyroidism, the main finding of HPT-JT syndrome, occurs in up to 95% of affected individuals; onset is typically in late adolescence or early adulthood. HPT-JT-associated primary hyperparathyroidism is usually caused by a single parathyroid adenoma. In approximately 10%-15% of individuals, primary hyperparathyroidism is caused by parathyroid carcinoma. Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome. Although benign, these tumors can be locally aggressive and may continue to enlarge if not treated. Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) Wilms tumor have also been reported. Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome. Parathyroid carcinoma. Most parathyroid carcinomas are functional, resulting in hyperparathyroidism and a high serum calcium level; however, nonfunctioning parathyroid carcinomas are also rarely described in individuals with a CDC73-related disorder. A germline CDC73 pathogenic variant has been identified in 20%-29% of individuals with apparently sporadic parathyroid carcinoma. Familial isolated hyperparathyroidism (FIHP). FIHP is characterized by primary hyperparathyroidism without other associated syndromic features. Individuals with CDC73-related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a CDC73 pathogenic variant has not been identified.</Attribute>
                <XRef ID="NBK3789" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7329" />
                <XRef ID="7329" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301744</ID>
                <ID Source="BookShelf">NBK3789</ID>
              </Citation>
              <XRef ID="143" DB="Orphanet" />
              <XRef ID="C0687150" DB="MedGen" />
              <XRef ID="MONDO:0012004" DB="MONDO" />
              <XRef Type="MIM" ID="608266" DB="OMIM" />
              <XRef Type="primary" ID="HP:0006780" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7864778" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_024529.5:c.626_629del|OMIM:145000" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004215585" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_024529.5:c.626_629del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="145000" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4258836" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="4822199|MedGen:C0687150" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002240719" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23029104</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32590342</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12434154</ID>
          </Citation>
          <Comment>This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with parathyroid carcinoma (PMID: 23029104, 32590342). This sequence change creates a premature translational stop signal (p.Lys209Argfs*9) in the CDC73 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CDC73 are known to be pathogenic (PMID: 12434154).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CDC73" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.193111092_193111095del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0687150" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4258836" TraitType="Disease" MappingType="XRef" MappingValue="C0687150" MappingRef="MedGen">
        <MedGen CUI="C0687150" Name="Parathyroid carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7864778" TraitType="Disease" MappingType="XRef" MappingValue="145000" MappingRef="OMIM">
        <MedGen CUI="C1840402" Name="Hyperparathyroidism 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

